You can’t mention biotech leaders without mentioning Clay Siegall, the exceptional Chief Executive Officer of Seattle Genetics. He is, without a doubt, an asset to the medical community and has contributed a lot in the fight against the dreaded diseases like cancer. Through Seattle Genetics, Siegall introduced the first ADC technology, an innovation that led to the release of effective antibody-drug conjugates like ADCETRIS. Most of Siegall’s ADCs have attained the FDA approval and are used by many specialists for treatment around the world. ADCETRIS, for instance, has an enormous global impact and is accepted in more than 60 countries.
Siegall has been leading Seattle Genetics since its inception in 1998. Apart from being the CEO, the exceptional scientist is also the President and Chairman of the Board of Directors. As the CEO of the company, Siegall is responsible for advancement and promotion of the ADC technology. He also spearheads all the company’s fundraising activities. To date, Siegall has helped Seattle Genetics get more than $1.2 billion through various means of fundraising. This huge amount of money has allowed Seattle Genetics to make significant strides in the fight against cancer.
According to the latest news from Seattle Genetics, Siegall believes that there is more to be done, and he won’t slow down his enthusiasm and the dream of addressing the challenges associated with cancer once and for all. He spends most of his time conducting medical investigations. Currently, Siegall holds more than 15 patents that mainly focus on the topic of cancer treatments.
The remarkable CEO is also an author and has published more than 70 scientific articles. In these articles, Clay shares in-depth knowledge and research findings with scientists and the medical community. He is also the brains behind the top scientific journals, and he gives fellow scientists an opportunity to publish their medical articles. Siegall has received numerous awards throughout his career due to his scientific findings and leadership skills.
Siegall is a Ph.D. holder. He earned his B.S in Zoology from the University of Maryland. Before Seattle Genetics, Siegall worked at Bristol-Myers Squibb Pharmaceutical Research Institute until 1997.